DECLARE-TIMI 58: Participants' baseline characteristics.

Itamar RazOfri MosenzonMarc P BonacaAvivit CahnEri T KatoMichael G SilvermanDeepak L Bhatt Lawrence Alan LeiterDarren K McGuireJohn P H WildingIngrid A M Gause-NilssonAnna M LangkildePeter A JohanssonMarc S SabatineStephen D Wiviott

Published in: Diabetes, obesity & metabolism (2018)

The DECLARE-TIMI 58 trial is expected to provide conclusive data on the effect of treatment with dapagliflozin in addition to standard of care, on CV outcomes in a broad patient population with type 2 diabetes and CVD or MRF for CVD.

Keyphrases

healthcare
palliative care
case report
study protocol
phase iii
quality improvement
big data
phase ii
pain management
machine learning
metabolic syndrome
open label
combination therapy
skeletal muscle
smoking cessation
insulin resistance
glycemic control
placebo controlled